31st January 2016

Atnahs Acquires Naproxen Suspension in the US

Basildon, UK, January 31 2016 – Atnahs Pharma US Limited (“Atnahs”) is pleased to announce the acquisition of Naproxen Suspension from Pediapharm Inc. in a total transaction of US$4.25 million.

The product is currently awaiting Food and Drug Administration (“FDA”) Supplement Approval regarding the manufacturing site transfer.

For further information: pharmanovia.com

Pharmanovia Press Contact
Kate Antonopoulos, Corporate Marketing & Communications Manager
Phone: +44 1268 943857
Email: katerina.antonopoulos@pharmanovia.com